Evidence-based treatment of chronic immune-mediated neuropathies (Q37550515)

21 August 2017

1 reference

title

Evidence-based treatment of chronic immune-mediated neuropathies (English)

1 reference

21 August 2017

1

1 reference

21 August 2017

Jean-Michel Vallat

2

1 reference

21 August 2017

language of work or name

English

0 references

publication date

1 August 2009

1 reference

Expert Opinion on Pharmacotherapy

21 August 2017

published in

1 reference

21 August 2017

volume

10

1 reference

21 August 2017

issue

11

1 reference

21 August 2017

page(s)

1741-1754

1 reference

Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656560903036095

Chronic inflammatory demyelinating polyradiculoneuropathy. A clinical and electrophysiological study of 92 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903036095

Chronic dysimmune demyelinating polyneuropathy: a clinical and electrophysiological study of 93 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903036095

"Chronic sensory demyelinating neuropathy": chronic inflammatory demyelinating polyneuropathy presenting as a pure sensory neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903036095

Recurrent polyneuropathies and their corticosteroid treatment; with five-year observations of a placebo-controlled case treated with corticotrophin, cortisone, and prednisone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903036095

Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903036095

Pulsed high dose dexamethasone treatment in chronic inflammatory demyelinating polyneuropathy: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903036095

Treatment of chronic inflammatory demyelinating polyneuropathy with pulsed oral steroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903036095

Treatment of dys-immune neuropathies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903036095

Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903036095

Treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903036095

Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903036095

Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903036095

Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903036095

A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903036095

Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903036095

High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903036095

Long term prognosis of chronic inflammatory demyelinating polyneuropathy: a five year follow up of 38 cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903036095

Successful autologous stem cell transplantation in a patient with chronic inflammatory demyelinating polyneuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903036095

Mycophenolate mofetil in dysimmune neuropathies: a preliminary study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903036095

Efficacy of mycophenolate mofetil in patients with chronic immune demyelinating polyneuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903036095

Mycophenolate (CellCept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903036095

Mycophenolate in treatment-resistant inflammatory neuropathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903036095

Treatment of chronic inflammatory demyelinating polyradiculoneuropathy with methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903036095

Randomised controlled trial of methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy (RMC trial): a pilot, multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903036095

Cyclosporin A in resistant chronic inflammatory demyelinating polyradiculoneuropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903036095

Treatment of chronic inflammatory demyelinating polyneuropathy with cyclosporin-A

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903036095

Intractable chronic inflammatory demyelinating polyneuropathy treated successfully with ciclosporin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903036095

Interferon beta-1a as an investigational treatment for CIDP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903036095

Sustained remission of CIDP associated with Evans syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903036095

Rituximab in chronic inflammatory demyelinating polyneuropathy associated with diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903036095

Multifocal acquired demyelinating neuropathy masquerading as motor neuron disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903036095

Motor Neuropathy with Proximal Multifocal Persistent Conduction Block, Fasciculations and Myokymia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903036095

Multifocal motor neuropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903036095

Electrophysiological diagnosis of motor neuron disease and pure motor neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903036095

Multifocal motor neuropathy with conduction block: a study of 24 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903036095

Multifocal motor neuropathy without overt conduction block

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903036095

Clinical spectrum of chronic acquired demyelinating polyneuropathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903036095

Multifocal motor neuropathy: response to human immune globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903036095

High-dose intravenous immunoglobulin therapy in multifocal motor neuropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903036095

Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903036095

Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903036095

Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903036095

Multifocal motor neuropathy: clinical and immunological features and response to IVIg in relation to the presence and degree of motor conduction block.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903036095

The long-term effect of intravenous immunoglobulin treatment in multifocal motor neuropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903036095

How long is IVIg effective in multifocal motor neuropathy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903036095

Multifocal motor neuropathy: long-term clinical and electrophysiological assessment of intravenous immunoglobulin maintenance treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903036095

Long term follow up of multifocal motor neuropathy with conduction block under treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903036095

Pure motor demyelinating neuropathy: deterioration after steroid treatment and improvement with intravenous immunoglobulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903036095

Plasmapheresis in multifocal motor neuropathy: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903036095

Long term effect of intravenous immunoglobulins and oral cyclophosphamide in multifocal motor neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903036095

Mycophenolate mofetil as adjunctive therapy for MMN patients: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903036095

A syndrome of asymmetric limb weakness with motor conduction block

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903036095

Chronic motor neuropathies: response to interferon-beta1a after failure of conventional therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903036095

Axonal neuropathy associated with monoclonal gammopathy of undetermined significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903036095

Peripheral neuropathies associated with monoclonal proteins: a clinical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903036095

Efficacy of intravenous immunoglobulin in patients with IgG monoclonal gammopathy and polyneuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903036095

Polyneuropathies associated with IgM monoclonal gammopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903036095

Myelin-Associated Glycoprotein Is the Antigen for a Monoclonal IgM in Polyneuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903036095

Immunoglobulin M Deposition in Cutaneous Nerves of Anti-Myelin-Associated Glycoprotein Polyneuropathy Patients Correlates With Axonal Degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903036095

The natural history of chronic demyelinating neuropathy associated with benign IgM paraproteinaemia. A clinical and neurophysiological study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903036095

Plasma exchange and chlorambucil in polyneuropathy associated with monoclonal IgM gammopathy. IgM-associated Polyneuropathy Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903036095

Intermittent cyclophosphamide and prednisone treatment of polyneuropathy associated with monoclonal gammopathy of undetermined significance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903036095

Successful treatment of IgM paraproteinaemic neuropathy with fludarabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903036095

Treatment of Waldenstrom's Macroglobulinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903036095

Cladribine in the treatment of IgM paraproteinemic polyneuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903036095

Hairy cell leukaemia complicated by anti-MAG paraproteinemic demyelinating neuropathy: resolution of neurological syndrome after cladribrine treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903036095

A randomised double blind trial versus placebo does not confirm the benefit of alpha-interferon in polyneuropathy associated with monoclonal IgM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903036095

The role of IVIg in autoimmune neuropathies: the latest evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903036095

Rituximab in the treatment of peripheral neuropathy associated with monoclonal gammopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903036095

Treatment of IgM antibody associated polyneuropathies using rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903036095

LONG-TERM EFFECT OF RITUXIMAB IN ANTI-MAG POLYNEUROPATHY

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903036095

Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903036095

Chronic inflammatory demyelinating polyneuropathy--update on pathogenesis, diagnostic criteria and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903036095

Intranervous immunoglobulin deposits: an underestimated mechanism of neuropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903036095

Contribution of electron microscopy to the study of neuropathies associated with an IgG monoclonal paraproteinemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903036095

Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single-blinded cross-over trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903036095

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903036095

Remission of chronic inflammatory demyelinating polyneuropathy after alemtuzumab (Campath 1H).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903036095

Oral fingolimod (FTY720) for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903036095

Treating multiple sclerosis with monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903036095

Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903036095

10.1517/14656560903036095

21 January 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference